IDEXX Laboratories, Inc. (IDXX) earnings on August 4, 2026

IDXX price around the earnings

588.09

Change: +3.6%

Start of the measured window End of the measured window

561.01 581.28 601.55 621.83 567.84

August 4, 2026

Price: green if it ends above the starting price; red if it ends below
Start of the measured window
End of the measured window
Market open
Starting price

Price series around the event

Prior thesis

Prior outlook: Optimistic Outcome: Accurate

Thesis published: 2026-08-04, 08:51 UTC
Results released: 2026-08-04, 10:30 UTC

Strong expectations, scenario optimistic

Experts see a strong setup because the company has beaten earnings expectations in recent quarters and analysts point to an optimistic scenario. A recent downgrade and heavy retail interest are the main cautions.

Context analyzed before publication

Summary: Strong expectations, scenario optimistic
Playbook: The stock has been rising steadily and is outperforming the broader market, though it sits near a resistance level. Retail interest is high, which historically can add volatility around earnings.
Trend: Analyst confidence improving over recent days

Analysts

Drivers

Analysts Positive
Analysts rate the stock a buy and cite a price target about 24.5% above the current price. One firm downgraded it, but still keeps a target above the current price.

Evidence

Analyst consensus: Buy
Consensus average (1-5): 2.13
Analysts covering the stock: 14
Average price target: 707
Lowest price target: 470
Highest price target: 805
Upside to price target: 24.5%
Quarterly earnings growth: 14.7%
Revenue growth: 14.3%
Forward EPS: 16.52
Trailing EPS: 13.59
Analyst moves in the last 60 days: 1

Strong buy: 4
Buy: 5
Hold: 5
Sell: 0
Strong sell: 1

Strong buy: 4
Buy: 5
Hold: 5
Sell: 0
Strong sell: 1

July 27, 2026 · UBS: Maintains rating (Neutral → Neutral)

News and sentiment

Evidence

Sentiment

Sentiment: Constructive
Mention volume: High
Normalized volume: 99%

News

Sources (1)

UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $620 (opens in a new tab) — Benzinga

Technicals

Drivers

Technical Positive
The stock has risen over the past two weeks and is outperforming the broader market. It is currently near a resistance level that could cap further gains.

Evidence

Price when the context was analyzed: 567.63
Average true range (ATR): 2.8%
Distance to 52-week high: -27.1%
14-day change (14d): +0.7%
30-day change (32d): +1.5%
30-day relative strength: +3.2%
QQQ change (32d): -1.8%
Nearest support: 561.35
Distance to nearest support: 1.1%
Nearest resistance: 567.64
Distance to nearest resistance: 0%
Volume accumulation ratio (14d / 46d): 1.05

Major: 561.35 (1.1% away, 0.39 ATR, 59 touches)
Major: 555.06 (2.2% away, 0.78 ATR, 36 touches)
Major: 548.75 (3.3% away, 1.17 ATR, 53 touches)

Major: 567.64 (0% away, 0 ATR, 30 touches)
Major: 574.37 (1.2% away, 0.42 ATR, 22 touches)
Major: 578.48 (1.9% away, 0.67 ATR, 31 touches)

Trends

Evidence

Average earnings surprise: +6.2%

May 5, 2026: actual EPS 3.47 vs estimate 3.41 (surprise +1.7%)
February 2, 2026: actual EPS 3.08 vs estimate 2.94 (surprise +4.8%)
November 3, 2025: actual EPS 3.4 vs estimate 3.15 (surprise +8.1%)
August 4, 2025: actual EPS 3.63 vs estimate 3.3 (surprise +10.0%)

Expected move

Drivers

Past earnings Positive
The company has beaten earnings expectations in every recent quarter, with an average surprise of +6.2%. The last few quarters also came in above forecasts.

Implied move: +3.0%
Source: Options chain

Reactions over its last 20 earnings

Median move: 4.8%
75th percentile move: 9.1%
90th percentile move: 11.6%
Up / down moves: 10 / 10
Average up move: +8.9%
Average down move: -4.4%

Monitoring and close

What IDEXX Laboratories, Inc. reported

Status: Finished

Actual EPS	4.27
EPS estimate	3.96
EPS surprise	+7.8%
Revenue	$1,217 million
Revenue estimate	$1,201 million
Revenue surprise	+1.3%

IDEXX beat Q2 expectations and raised annual guidance. Shares rose nearly 4% premarket, reflecting optimism.

Sources (14)

IDEXX Laboratories Q2 Earnings Call Highlights (opens in a new tab) — MarketBeat
IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market (opens in a new tab) — Zacks
Why Is IDEXX Laboratories Stock Gaining Tuesday? (opens in a new tab) — Benzinga
IDEXX Laboratories Q2 2026 Earnings Call Transcript (opens in a new tab) — Benzinga
Idexx (IDXX) Reports Q2 Earnings: What Key Metrics Have to Say (opens in a new tab) — Zacks
IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript (opens in a new tab) — SeekingAlpha
SR Inc Net Zero Consortium for Buyers: Seven-Buyer Aggregation for 180 MW of Millers Branch Solar Now Online (opens in a new tab) — Yahoo
IDEXX Laboratories Shares Climb After Earnings Beat and Improved Full-Year Outlook (opens in a new tab) — InvestorsHub
Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates (opens in a new tab) — Zacks
IDEXX Laboratories (NASDAQ:IDXX) Shares Rise on Q2 Earnings Beat and Improved Outlook (opens in a new tab) — ChartMill
IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.675B-$4.760B to $4.700B-$4.745B vs $4.711B Est (opens in a new tab) — Benzinga
IDEXX beat expectations with earnings of $4.27 per share and sales of $1.217 billion, above forecasts. — Benzinga
IDEXX Laboratories Q2 EPS $4.27 Beats $3.96 Estimate, Sales $1.217B Beat $1.201B Estimate (opens in a new tab) — Benzinga
IDEXX Laboratories Announces Second Quarter Results (opens in a new tab) — Yahoo

Pre-market second reading after the results

Verdict: Beat expectations

Heading into the open, results beat expectations on both earnings and revenue, and the price is indicating +4.0% pre-market, a move in line with the stock's usual reaction (about 5%). The figures confirm the optimistic scenario. In the 1,275 similar cases in our market history, the close held that direction 86% of the time.

How the stock reacted

Outcome: Accurate
Consolidated: +3.6%
Max favorable move (MFE): 9.7%
Max adverse move (MAE): 0%